5.2 Number of Participants The number of participants for this study will be approximately 234. Up to approximately 34 of these participants may be treated with monotherapy (Preliminary Safety Cohorts and Part A); approximately 6 evaluable participants may be treated at each dose level for Parts B1 and C1; approximately 6-12 evaluable participants may be treated at each dose level for Parts B2 and C2; up to 6 additional evaluable participants may be treated in Parts B and/or C, at a recommended BMS-986226 dose regimen for Parts D and/or E to better characterize the safety, PK, and PD profile; approximately 80 participants will be treated in combination expansion arms, Parts D and E. Additional information on sample size determination can be found in Section 10.1 .